{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:33:25Z","timestamp":1777937605269,"version":"3.51.4"},"reference-count":5,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1177\/13524585221137254","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T01:24:00Z","timestamp":1669598640000},"page":"153-154","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient\u2014Commentary"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-8035","authenticated-orcid":false,"given":"Cristina","family":"Valencia-Sanchez","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"bibr1-13524585221137254","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"bibr2-13524585221137254","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"bibr3-13524585221137254","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025"},{"key":"bibr4-13524585221137254","unstructured":"US Food and Drug Administration. Genentech. Enspryng\u00ae (satralizumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761149s000lbl.pdf (accessed 13 October 2022)."},{"key":"bibr5-13524585221137254","unstructured":"European Medicines Agency. Enspryng\u00ae (satralizumab) [package leaflet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enspryng-epar-product-information_en.pdf (accessed 13 October 2022)."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585221137254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585221137254","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585221137254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:10:59Z","timestamp":1777695059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585221137254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/13524585221137254"],"URL":"https:\/\/doi.org\/10.1177\/13524585221137254","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]}}}